[HTML][HTML] Sarcoidosis: a clinical overview from symptoms to diagnosis

P Sève, Y Pacheco, F Durupt, Y Jamilloux… - Cells, 2021 - mdpi.com
Sarcoidosis is a multi-system disease of unknown etiology characterized by the formation of
granulomas in various organs. It affects people of all ethnic backgrounds and occurs at any …

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?

P Sève, C Dumontet - The lancet oncology, 2008 - thelancet.com
On the basis of preclinical studies that show overexpression of class III β-tubulin is associated
with resistance to tubulin-binding agents, several investigators have addressed the …

Therapeutic options in VEXAS syndrome: insights from a retrospective series

…, CA Durel, JC Lega, F Barraco, P Sève… - Blood, The Journal …, 2021 - ashpublications.org
Bourbon et al describe a series of 19 patients from France with VEXAS syndrome, including
a novel genetic aberration in UBA1, and the outcomes of treatment for those with and those …

IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry

M Ebbo, L Daniel, M Pavic, P Sève, M Hamidou… - Medicine, 2012 - journals.lww.com
IgG4-related systemic disease is now recognized as a systemic disease that may affect
various organs. The diagnosis is usually made in patients who present with elevated IgG4 in …

Chemoresistance in non-small cell lung cancer

P Sève, C Dumontet - Current Medicinal Chemistry-Anti-Cancer …, 2005 - ingentaconnect.com
The treatment of advanced non-small-cell lung cancer (NSCLC is based on the combination
of platin and one of the following agents: taxanes, gemcitabine, vinorelbine or irinotecan. …

Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel

P Seve, J Mackey, S Isaac, O Tredan, PJ Souquet… - Molecular Cancer …, 2005 - AACR
Both fundamental and clinical studies suggest that class III β-tubulin expression is associated
with resistance to taxanes and constitutes a prognostic factor in several solid tumors. In this …

JAK inhibitors for the treatment of autoimmune and inflammatory diseases

…, L Vuitton, M Gerfaud-Valentin, S Kerever, P Seve - Autoimmunity …, 2019 - Elsevier
Cytokines play a central role in the pathophysiology of autoimmune and inflammatory diseases.
Several cytokines signal through the JAK-STAT pathway, which is now recognized as a …

[HTML][HTML] Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative

…, A Rothova, S Schwartzman, P Seve… - Ophthalmology, 2018 - Elsevier
Topic An international, expert-led consensus initiative to develop systematic, evidence-based
recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical …

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: multicenter study of 124 patients

…, C Salvarani, M Lambert, P Bielefeld, P Seve… - Journal of …, 2015 - Elsevier
Objective To report the efficacy and safety of anti-TNF agents in patients with severe and/or
refractory manifestations of Behçet's disease (BD). Methods We performed a multicenter …

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer

LP Jordheim, P Sève, O Trédan, C Dumontet - The lancet oncology, 2011 - thelancet.com
The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of
cell proliferation, cell migration, tumour and metastasis development, and the synthesis of …